Johns Hopkins Study: Early Treatment With Plasma May Reduce Long COVID Risk
Johns Hopkins-led research finds early treatment with plasma from recovered COVID-19 patients reduces “long COVID” risks, with inflammation-inducing interleukin-6 (IL6) playing a key role in symptom development.
https://scitechdaily.com/johns-hopkins-study-early-treatment-with-plasma-may-reduce-long-covid-risk/ #Early #Treatment #Plasma #Reduce #LongCOVID #Risk